xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05986227</url>
    </required_header>
    <id_info>
      <org_study_id>2022111621481500</org_study_id>
      <nct_id>NCT05986227</nct_id>
    </id_info>
    <brief_title>The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):</brief_title>
    <acronym>SCORPIO</acronym>
    <official_title>The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-oncology Therapy of HER2-negative Gastroesophageal Adenocarcinoma (Siewert I/II): a Multicenter, Open-label, Randomized Controlled, Phase 1b/2 Trial (SCORPIO/NCCES05)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The addition of immunotherapy to chemotherapy improves outcomes in patients with&#xD;
        HER2-negative gastroesophageal adenocarcinoma (GEA), and investigators aim to explore its&#xD;
        role in the perioperative setting. Moreover, optimizing the timing schedule of these two&#xD;
        therapies is critical when balancing efficacy and safety. This Chinese, multicenter,&#xD;
        open-label phase 1b/2 trial will evaluate the efficacy and toxicity of perioperative folinic&#xD;
        acid, fluoro-uracil, oxali-platin (FOLFOX), and toripalimab (JS001, a novel PD-1 inhibitor)&#xD;
        in combination at various schedules in the neoadjuvant setting in patients with HER2-negative&#xD;
        resectable GEA: three cycles each in Arm A: FOLFOX (D1, q2w) followed by toripalimab (D3, 3&#xD;
        mg/kg, q2w); Arm B: concurrent FOLFOX (D1, q2w) combined with toripalimab (D1, 3 mg/kg, q2w);&#xD;
        Arm C: toripalimab (D1, 3 mg/kg, q2w) followed by FOLFOX (D3, q2w); Arm D: FOLFOX (D1, q2w)&#xD;
        alone. The primary end-point is the dose-limiting toxicity in Phase 1b and the pathological&#xD;
        complete response rate in Phase 2; secondary end-points include major pathologic response,&#xD;
        disease-free survival, and event-free survival.A fixed sample size of 126 patients is used in&#xD;
        this study, with a safety run-in period (n = 6) and cohort expansion period (n = 24), a&#xD;
        dropout rate of 5% within 12 months of follow-up. Each arm receives three cycles of FOLFOX&#xD;
        (D1, q2w) followed by 15 cycles of toripalimab (D1, 240 mg, q3w) in the neoadjuvant setting.&#xD;
        Pre-treatment biopsies, post-resection specimens, serial liquid biopsy, and gut microbiota&#xD;
        samples on treatment will be collected to explore the biomarkers' predictive value on diverse&#xD;
        schedule efficacy and safety.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This Chinese, multicenter, open-label phase 1b/2 trial will evaluate the efficacy and&#xD;
        toxicity of perioperative folinic acid, fluoro-uracil, oxali-platin (FOLFOX), and toripalimab&#xD;
        (JS001, a novel PD-1 inhibitor) in combination at various schedules in the neoadjuvant&#xD;
        setting in patients with HER2-negative resectable GEA: three cycles each in Arm A: FOLFOX&#xD;
        (D1, q2w) followed by toripalimab (D3, 3 mg/kg, q2w); Arm B: concurrent FOLFOX (D1, q2w)&#xD;
        combined with toripalimab (D1, 3 mg/kg, q2w); Arm C: toripalimab (D1, 3 mg/kg, q2w) followed&#xD;
        by FOLFOX (D3, q2w); Arm D: FOLFOX (D1, q2w) alone. The primary end-point is the&#xD;
        dose-limiting toxicity in Phase 1b and the pathological complete response rate in Phase 2;&#xD;
        secondary end-points include major pathologic response, disease-free survival, and event-free&#xD;
        survival. A fixed sample size of 126 patients is used in this study, with a safety run-in&#xD;
        period (n = 6) and cohort expansion period (n = 24), a dropout rate of 5% within 12 months of&#xD;
        follow-up. Each arm receives three cycles of FOLFOX (D1, q2w) followed by 15 cycles of&#xD;
        toripalimab (D1, 240 mg, q3w) in the neoadjuvant setting. Pre-treatment biopsies,&#xD;
        post-resection specimens, serial liquid biopsy, and gut microbiota samples on treatment will&#xD;
        be collected to explore the biomarkers' predictive value on diverse schedule efficacy and&#xD;
        safety.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 1, 2023</start_date>
    <completion_date type="Anticipated">July 1, 2026</completion_date>
    <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>DLT</measure>
      <time_frame>through study completion,an average of 1.5 years</time_frame>
      <description>Phase 1b: safety of the combination regimen in different drug treatment sequences, i.e., dose-limiting toxicity (DLT).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PCR</measure>
      <time_frame>0.5 year</time_frame>
      <description>Phase II: efficacy of different sequential combinations of drugs, i.e., postoperative pathological complete response rate (pCR).</description>
    </primary_outcome>
    <number_of_arms>4</number_of_arms>
    <enrollment type="Anticipated">126</enrollment>
    <condition>Gastroesophageal Adenocarcinoma</condition>
    <arm_group>
      <arm_group_label>FOLFOX(D1)was combined with toripalimab(D3)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>FOLFOX(D1)was combined with toripalimab(D1)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>FOLFOX(D3) was combined with toripalimab(D1)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>FOLFOX(D1)</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>toripalimab FOLFOX</intervention_name>
      <description>Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)</description>
      <arm_group_label>FOLFOX(D1)</arm_group_label>
      <arm_group_label>FOLFOX(D1)was combined with toripalimab(D1)</arm_group_label>
      <arm_group_label>FOLFOX(D1)was combined with toripalimab(D3)</arm_group_label>
      <arm_group_label>FOLFOX(D3) was combined with toripalimab(D1)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age &gt;/= 18 years;&#xD;
  &#xD;
            -  Male or Female;&#xD;
  &#xD;
            -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;&#xD;
  &#xD;
            -  Histologically or cytologically confirmed locally advanced adenocarcinoma of esophagus&#xD;
               or gastroesophageal junction (Siewert type I/II);&#xD;
  &#xD;
            -  Human epidermal growth factor receptor 2 (HER2)-negative tumors;&#xD;
  &#xD;
            -  Clinical staging cT2-T4aNanyM0 or TanyN+M0 (UICC/AJCC 8th edition), potentially&#xD;
               resectable disease;&#xD;
  &#xD;
            -  Adequate hematologic and end organ function based on laboratory results obtained&#xD;
               within 14 days prior to initiation of study treatment;&#xD;
  &#xD;
            -  For women of childbearing potential: agreement to remain abstinent；no evidence of&#xD;
               pregnancy within 72 hours before the start of study regimen;&#xD;
  &#xD;
            -  Must be willing and able to provide written informed consent.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Known unresectable disease，cT4b disease invading aorta or trachea;&#xD;
  &#xD;
            -  Known distant metastases，including supraclavicular lymph nodal disease；&#xD;
  &#xD;
            -  Uncontrollable pleural or pericardial effusion，or ascites requiring repeated&#xD;
               interventions;&#xD;
  &#xD;
            -  Prior chemotherapy, immunotherapy, targeted therapy, thoracic radiotherapy or prior&#xD;
               surgical resection for an esophageal tumor;&#xD;
  &#xD;
            -  Poor nutritional status, BMI &lt; 18.5 Kg/m2; if symptomatic nutritional support is&#xD;
               corrected before randomization, enrollment may continue to be considered after&#xD;
               assessment by the principal investigator;&#xD;
  &#xD;
            -  History of allergy to biological drugs produced by Chinese hamster ovary cells, any&#xD;
               component of toripalimab, tegafur, oxaliplatin or other platinum drugs;&#xD;
  &#xD;
            -  History of severe allergic, allergic reactions, or other hypersensitivity to chimeric&#xD;
               or humanized antibodies or fusion proteins;&#xD;
  &#xD;
            -  Patients with prior malignancies are eligible if they have been disease-free for &gt; 5&#xD;
               years and are deemed by their physician to be at low risk for recurrence. Patients&#xD;
               with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ&#xD;
               of the cervix, or carcinoma in situ of the colon or rectum that have been effectively&#xD;
               treated are eligible, even if these conditions were diagnosed within 5 years prior to&#xD;
               enrollment；&#xD;
  &#xD;
            -  History of any active autoimmune disease or autoimmune disease, including myasthenia&#xD;
               gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid&#xD;
               arthritis, inflammatory bowel disease, antiphospholipid syndrome-related vascular&#xD;
               thrombosis, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome,&#xD;
               multiple sclerosis, vasculitis, glomerulonephritis, etc.; hypothyroidism (hormone&#xD;
               replacement therapy can be considered to be included);&#xD;
  &#xD;
            -  History of immunosuppressive drugs, or systemic hormones used to achieve&#xD;
               immunosuppressive purposes (dose &gt; 10 mg/day prednisone or equivalent dose) within 2&#xD;
               weeks before the first use of the study drug; in the absence of active autoimmune&#xD;
               diseases, inhaled or local steroids are allowed and doses &gt; 10 mg/day prednisone or&#xD;
               equivalent doses of adrenocorticotropic hormone replacement;&#xD;
  &#xD;
            -  History of type 1 diabetes, whose blood glucose is controlled after treatment with a&#xD;
               stable dose of insulin dosing regimen may be enrolled in this study;&#xD;
  &#xD;
            -  History of live attenuated vaccines are received within 4 weeks before the first use&#xD;
               of the study drug;&#xD;
  &#xD;
            -  History of major surgery or severe trauma within 4 weeks before the first use of the&#xD;
               study drug;&#xD;
  &#xD;
            -  History of eczema, psoriasis, lichen simplex chronicus, or dermatologic manifestations&#xD;
               of vitiligo (eg, patients with psoriatic arthritis were excluded from the study) were&#xD;
               permitted to enroll in this study if they met the following conditions: a) had rash&#xD;
               coverage less than 10% of body surface area (BSA); b) had adequately controlled&#xD;
               disease at baseline and required only low-potency topical steroid therapy; c) did not&#xD;
               have an acute exacerbation of the underlying disease within the past 12 months without&#xD;
               the need for PUVA (psoralen plus ultraviolet A radiation), methotrexate, retinoids,&#xD;
               biologics, oral calcineurin inhibitors, high-titer, or oral steroid therapy for]；&#xD;
  &#xD;
            -  History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis&#xD;
               obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial pneumonia, or&#xD;
               evidence of active pneumonia on screening chest CT scan;&#xD;
  &#xD;
            -  History of immunodeficiency, including HIV test positive, or suffering from other&#xD;
               acquired or congenital immunodeficiency diseases, or a history of organ&#xD;
               transplantation or allogeneic bone marrow transplantation;&#xD;
  &#xD;
            -  Uncontrolled cardiac clinical symptoms or diseases, including but not limited to: a)&#xD;
               NYHA class II or higher heart failure; b) unstable angina; c) myocardial infarction&#xD;
               within 1 year; d) clinically significant supraventricular or ventricular arrhythmia&#xD;
               that remains poorly controlled without or after clinical intervention.&#xD;
  &#xD;
            -  Known hereditary or acquired bleeding and thrombophilia (such as hemophilia,&#xD;
               coagulation dysfunction, thrombocytopenia, etc.);&#xD;
  &#xD;
            -  Known serious infection (CTCAE &gt; 2) within 4 weeks before the first use of the study&#xD;
               drug, such as severe pneumonia requiring hospitalization, bacteremia, infectious&#xD;
               complications, etc.; baseline chest imaging showed active pulmonary inflammation,&#xD;
               symptoms and signs of infection within 14 days before the first use of the study drug&#xD;
               or oral or intravenous antibiotics, except for the prophylactic use of antibiotics;&#xD;
  &#xD;
            -  Active pulmonary tuberculosis infection detected by medical history or CT examination,&#xD;
               or history of active pulmonary tuberculosis infection within 1 year before enrollment,&#xD;
               or history of active pulmonary tuberculosis infection more than 1 year ago but without&#xD;
               regular treatment;&#xD;
  &#xD;
            -  Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (hepatitis C&#xD;
               antibody positive, and HCV RNA above the lower limit of detection of the analytical&#xD;
               method);&#xD;
  &#xD;
            -  Pregnant or lactating women;&#xD;
  &#xD;
            -  Other factors that may lead to forced halfway termination of the study as judged by&#xD;
               the investigator, such as having other serious diseases (including mental illness)&#xD;
               requiring concomitant treatment, alcoholism, drug abuse, family or social factors that&#xD;
               may affect the safety or compliance of the subject.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>75 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <verification_date>November 2022</verification_date>
    <study_first_submitted>April 30, 2023</study_first_submitted>
    <study_first_submitted_qc>August 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 14, 2023</study_first_posted>
    <last_update_submitted>August 3, 2023</last_update_submitted>
    <last_update_submitted_qc>August 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>GEA</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Adenocarcinoma</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05986227
  org study id: 2022111621481500
  nct id: NCT05986227
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  The addition of immunotherapy to chemotherapy improves outcomes in patients with
        HER2-negative gastroesophageal adenocarcinoma (GEA), and investigators aim to explore its
        role in the perioperative setting. Moreover, optimizing the timing schedule of these two
        therapies is critical when balancing efficacy and safety. This Chinese, multicenter,
        open-label phase 1b/2 trial will evaluate the efficacy and toxicity of perioperative folinic
        acid, fluoro-uracil, oxali-platin (FOLFOX), and toripalimab (JS001, a novel PD-1 inhibitor)
        in combination at various schedules in the neoadjuvant setting in patients with HER2-negative
        resectable GEA: three cycles each in Arm A: FOLFOX (D1, q2w) followed by toripalimab (D3, 3
        mg/kg, q2w); Arm B: concurrent FOLFOX (D1, q2w) combined with toripalimab (D1, 3 mg/kg, q2w);
        Arm C: toripalimab (D1, 3 mg/kg, q2w) followed by FOLFOX (D3, q2w); Arm D: FOLFOX (D1, q2w)
        alone. The primary end-point is the dose-limiting toxicity in Phase 1b and the pathological
        complete response rate in Phase 2; secondary end-points include major pathologic response,
        disease-free survival, and event-free survival.A fixed sample size of 126 patients is used in
        this study, with a safety run-in period (n = 6) and cohort expansion period (n = 24), a
        dropout rate of 5% within 12 months of follow-up. Each arm receives three cycles of FOLFOX
        (D1, q2w) followed by 15 cycles of toripalimab (D1, 240 mg, q3w) in the neoadjuvant setting.
        Pre-treatment biopsies, post-resection specimens, serial liquid biopsy, and gut microbiota
        samples on treatment will be collected to explore the biomarkers' predictive value on diverse
        schedule efficacy and safety.
  This Chinese, multicenter, open-label phase 1b/2 trial will evaluate the efficacy and
        toxicity of perioperative folinic acid, fluoro-uracil, oxali-platin (FOLFOX), and toripalimab
        (JS001, a novel PD-1 inhibitor) in combination at various schedules in the neoadjuvant
        setting in patients with HER2-negative resectable GEA: three cycles each in Arm A: FOLFOX
        (D1, q2w) followed by toripalimab (D3, 3 mg/kg, q2w); Arm B: concurrent FOLFOX (D1, q2w)
        combined with toripalimab (D1, 3 mg/kg, q2w); Arm C: toripalimab (D1, 3 mg/kg, q2w) followed
        by FOLFOX (D3, q2w); Arm D: FOLFOX (D1, q2w) alone. The primary end-point is the
        dose-limiting toxicity in Phase 1b and the pathological complete response rate in Phase 2;
        secondary end-points include major pathologic response, disease-free survival, and event-free
        survival. A fixed sample size of 126 patients is used in this study, with a safety run-in
        period (n = 6) and cohort expansion period (n = 24), a dropout rate of 5% within 12 months of
        follow-up. Each arm receives three cycles of FOLFOX (D1, q2w) followed by 15 cycles of
        toripalimab (D1, 240 mg, q3w) in the neoadjuvant setting. Pre-treatment biopsies,
        post-resection specimens, serial liquid biopsy, and gut microbiota samples on treatment will
        be collected to explore the biomarkers' predictive value on diverse schedule efficacy and
        safety.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: DLT
  time frame: through study completion,an average of 1.5 years
  description: Phase 1b: safety of the combination regimen in different drug treatment sequences, i.e., dose-limiting toxicity (DLT).
  measure: PCR
  time frame: 0.5 year
  description: Phase II: efficacy of different sequential combinations of drugs, i.e., postoperative pathological complete response rate (pCR).
  arm group label: FOLFOX(D1)was combined with toripalimab(D3)
  arm group type: Experimental
  arm group label: FOLFOX(D1)was combined with toripalimab(D1)
  arm group type: Experimental
  arm group label: FOLFOX(D3) was combined with toripalimab(D1)
  arm group type: Experimental
  arm group label: FOLFOX(D1)
  arm group type: Active Comparator
  intervention type: Drug
  intervention name: toripalimab FOLFOX
  description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
  arm group label: FOLFOX(D1)
  arm group label: FOLFOX(D1)was combined with toripalimab(D1)
  arm group label: FOLFOX(D1)was combined with toripalimab(D3)
  arm group label: FOLFOX(D3) was combined with toripalimab(D1)
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 75 Years
  healthy volunteers: No
  responsible party type: Sponsor
  mesh term: Adenocarcinoma